Adam Hutchings
Overview
Explore the profile of Adam Hutchings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whittal A, Jommi C, de Pouvourville G, Taylor D, Annemans L, Schoonaert L, et al.
Int J Technol Assess Health Care
. 2022 May;
38(1):e43.
PMID: 35607832
No abstract available.
2.
Whittal A, Jommi C, de Pouvourville G, Taylor D, Annemans L, Schoonaert L, et al.
Int J Technol Assess Health Care
. 2022 Mar;
38(1):e23.
PMID: 35274602
Objectives: An increasing number of innovative therapies (e.g., gene- and cell-based treatments) have been developed in the past 20 years. Despite the significant clinical potential of these therapies, access delays...
3.
4.
Mestre-Ferrandiz J, Palaska C, Kelly T, Hutchings A, Parnaby A
Orphanet J Rare Dis
. 2019 Dec;
14(1):287.
PMID: 31829218
Background: Orphan medicinal product (OMP) prices are considered by some to be a challenge to the sustainability of healthcare expenditure. These concerns are compounded by the increasing number of OMPs...
5.
Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, et al.
Appl Health Econ Health Policy
. 2018 Aug;
16(6):803-817.
PMID: 30088251
Background: Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expenditure-driven by high...
6.
Annemans L, Ayme S, Le Cam Y, Facey K, Gunther P, Nicod E, et al.
Orphanet J Rare Dis
. 2017 Mar;
12(1):50.
PMID: 28283046
Rare diseases are an important public health issue with high unmet need. The introduction of the EU Regulation on orphan medicinal products (OMP) has been successful in stimulating investment in...
7.
Gutierrez L, Patris J, Hutchings A, Cowell W
Orphanet J Rare Dis
. 2015 May;
10:53.
PMID: 25935555
The European Orphan Medicinal Products (OMP) Regulation has successfully encouraged research to develop treatments for rare diseases resulting in the authorisation of new OMPs in Europe. While decisions on OMP...
8.
Hutchings A, Schey C, Dutton R, Achana F, Antonov K
Orphanet J Rare Dis
. 2014 Feb;
9:22.
PMID: 24524281
Background: The growth in expenditure on orphan medicinal products (OMP) across Europe has been identified as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account...
9.
Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A
Value Health
. 2013 Dec;
16(8):1163-9.
PMID: 24326170
Objective: To pilot the use of multicriteria decision analysis to establish and apply a framework of weighted attributes to value orphan medicinal products. Methods: Literature searches on the natural history...
10.
Wilson P, Hutchings A, Jeans A, Macdougall I
J Med Econ
. 2012 Sep;
16(1):108-14.
PMID: 22989163
Background: Historically, the Renal Unit at King's College Hospital used intravenous (IV) iron sucrose (IS) to treat iron deficiency anaemia in patients with chronic kidney disease who were not on...